Cargando…
p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
Oncogenic KRAS activation, inflammation and p53 mutation are key drivers of pancreatic cancer (PC) development. Here we report iASPP, an inhibitor of p53, as a paradoxical suppressor of inflammation and oncogenic KRAS(G12D)-driven PC tumorigenesis. iASPP suppresses PC onset driven by KRAS(G12D) alon...
Autores principales: | Miller, Paul, Akama-Garren, Elliot H., Owen, Richard P., Demetriou, Constantinos, Carroll, Thomas M., Slee, Elizabeth, Al Moussawi, Khatoun, Ellis, Michael, Goldin, Robert, O’Neill, Eric, Lu, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307949/ https://www.ncbi.nlm.nih.gov/pubmed/37270580 http://dx.doi.org/10.1038/s41418-023-01168-3 |
Ejemplares similares
-
Regulation of immunological tolerance by the p53-inhibitor iASPP
por: Akama-Garren, Elliot H., et al.
Publicado: (2023) -
Mutant Ras and inflammation-driven skin tumorigenesis is suppressed via a JNK-iASPP-AP1 axis
por: Al Moussawi, Khatoun, et al.
Publicado: (2022) -
Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NF-κB
por: Hu, Ying, et al.
Publicado: (2015) -
Nuclear iASPP may facilitate prostate cancer progression
por: Morris, E V, et al.
Publicado: (2014) -
iASPP regulates neurite development by interacting with Spectrin proteins
por: Wang, Junhao, et al.
Publicado: (2023)